Transcript
Announcer:
You’re listening to GLC on ReachMD. This Data Pulse, titled “EASD 2026 Data Pulse: Finerenone Evidence Across the CKD Spectrum” is provided by GLC
Dr. Rossing:
Hi, I'm Professor Peter Rossing from Copenhagen, Denmark. I'm here at EASD 2026 in Milan to talk about the INFINITY trial. INFINITY is a compilation of the chronic kidney disease trials with the nonsteroidal mineralocorticoid receptor antagonist finerenone. So it's the FIGARO and FIDELIO in type 2 diabetes with CKD and the FINE-CKD and the non-diabetic CKD compiled together. And the question we wanted to address with the analysis that was presented by me is an analysis taking care of the body mass index or obesity, does it matter for the effect of finerenone?
The question is relevant because it has been speculated and also observed in experimental models that with excess obesity, there is more aldosterone produced. And we have seen in heart failure trials that the benefit of finerenone is dependent on the body weight. So we wanted to see also in the INFINITY cohort whether there is an association or interaction with BMI. And what we see is that excess BMI is a risk factor, but that finerenone works independent of BMI. So in contrast to heart failure studies, we see that finerenone works both for those with normal weight and those with overweight.
This is an important message for clinical practice because we see in our population of patients with CKD both people that are obese and people with normal weight, and it is important to know that we can treat independent of obesity. We have also seen we can treat independent of other risk factors like glycemia or blood pressure, So in general we have contributed here at the EASD with data showing that finerenone works across many different patient characteristics.
Thank you very much for listening to this presentation at the EASD.
Announcer:
You have been listening to GLC on ReachMD. This Data Pulse is provided by Global Learning Collaborative. Thank you for listening!